Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Thc2.5
Tetrahydrocurcumin – Forschung
Überwiegend Mechanismus / Beobachtung
13 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Tetrahydrocurcumin sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus mittelwertigen randomisierten Studien, veröffentlicht 2006–2026 mit einer typischen Studiengröße von 19 Teilnehmenden.
Basierend auf 13 Studien · 1 RCT · 29 Teilnehmende insgesamt
Konfidenz
Geringe Konfidenz
Nach Outcome
Depression & mood
Zu wenige bewertete Studien2 Studien
Therapeutic & clinical
Zu wenige bewertete Studien2 Studien
Cognitive function
Zu wenige bewertete Studien1 Studie
Neuroprotection & brain agingNeuroprotective and mood signals come from animal studies and one 19-person adjunct pilot; not established · Unknown
Zu wenige bewertete Studien1 Studie
Heart & blood pressure
Zu wenige bewertete Studien1 Studie
Glucose & metabolic
Zu wenige bewertete Studien1 Studie
Liver health
Zu wenige bewertete Studien1 Studie
Aktives Forschungsgebiet
8 Studien in den letzten 5 Jahren
200620162026
1Übersicht2024
As a major active metabolite of curcumin, tetrahydrocurcumin had a wide range of biological activities and significant treatment effects on diseases [in preclinical studies].
Zhou M et al. · Food & Function (2024)
Comprehensive review of THC's preclinical activity across neurological disorders, metabolic syndrome, cancers, and inflammatory diseases.
Effects are mediated by MAPK, JAK/STAT, NF-κB, Nrf2, PI3K/Akt/mTOR, AMPK, and Wnt/β-catenin signalling.
Frames THC as a compound still under development for dietary supplements and drugs — i.e. not yet clinically established.
Various studies suggest that curcumin is a more potent antioxidant than THC.
Aggarwal BB et al. · Molecules (2014)
Mechanistic review directly comparing curcumin and its metabolite THC.
Best counter-evidence: curcumin (not THC) binds and inhibits many targets and is more effective at suppressing tumour-cell growth and viral entry; THC is superior only for select actions (e.g. glutathione peroxidase induction).
Undercuts the marketing premise that THC is simply a stronger, more bioavailable curcumin.
Curcumin metabolites exhibit activity comparable to, or even exceeding, the therapeutic potential of the parent compound in models of glucose and lipid metabolism.
Liu F et al. · The American Journal of Chinese Medicine (2026)
Systematic review of curcumin's reduced metabolites — including tetrahydrocurcumin — and their regulation of glucose and lipid homeostasis via PPARα, NF-κB, and PI3K/AKT.
Argues part of curcumin's metabolic activity may be mediated by metabolites like THC, which overcome curcumin's poor bioavailability.
Review-level and largely preclinical; no THC-specific human metabolic trial exists.
THC ameliorated nonalcoholic steatohepatitis induced by high-fat diet by restoring hepatocyte lipophagy through the mTORC1-TFEB signaling pathway.
Wu J et al. · Biomedicine & Pharmacotherapy (2024)
Rat NASH model plus a palmitate-stimulated cell model: THC improved liver function, lipid metabolism, inflammation, and oxidative stress by restoring lipophagy.
Preclinical liver/metabolic evidence — not yet tested in humans.
THC administration rescued learning and memory, and reduced Aβ burden in the hippocampus of APP/PS1 mice.
Xiao Y et al. · Biomedicine & Pharmacotherapy (2021)
Alzheimer mouse model plus BV-2 microglial cells: THC rescued learning and memory and reduced amyloid-β burden via anti-inflammatory and anti-apoptotic pathways.
Underpins the neuroprotection signal — but this is animal evidence; the only human neuro data is the 19-person depression pilot.
THC significantly attenuated agonist-induced granule secretion in human gel-filtered platelets in vitro ... leading to a decrease in thromboxane A2 generation.
Li W et al. · Thrombosis and Haemostasis (2022)
In-vitro study on human platelets plus an in-vivo thrombosis model: THC inhibited platelet granule secretion and thromboxane A2 via cPLA2/MAPK signalling.
Mechanistic basis for THC's antiplatelet/antithrombotic potential — and the reason for caution when combining it with anticoagulant or antiplatelet drugs.
Tetrahydrocurcumin ... resulted a significant reduction in blood glucose and significant increase in plasma insulin in diabetic rats, which proved its antidiabetic effect.
Murugan P, Pari L. · Basic & Clinical Pharmacology & Toxicology (2006)
Diabetic-rat study: oral THC (80 mg/kg, 45 days) lowered blood glucose, raised insulin, and reduced lipid peroxidation and serum/tissue lipids.
A foundational metabolic/antidiabetic preclinical study; the paper notes THC outperformed curcumin on some markers.
A randomized, open-label, parallel-group pilot trial enrolled 19 patients with major depressive disorder who received either escitalopram or escitalopram plus tetrahydrocurcumin for 29 days.
Guo Y et al. · Molecular Neurobiology (2025)
Small (n=19) randomized, open-label pilot adding 200 mg/day THC to escitalopram for major depressive disorder.
Reported greater improvement in depression scores with the THC add-on, alongside anti-inflammatory mechanistic findings.
Too small and unblinded to establish efficacy — hypothesis-generating only.